Home › NCT05837663
Trifecta-Lung cfDNA-MMDx Study
RecruitingObservational study
Trifecta-Lung cfDNA-MMDx Study: Comparing the Dd-cfDNA Test to MMDx Microarray Test and Central HLA Antibody Test
Who can join
Ages 18 and older · All sexes
Full eligibility criteria
Inclusion Criteria: Adult, Older adult Exclusion Criteria: Patients will be excluded from the study if they decline participation Are unable to give informed consent. Recipients of multiple organs, cancer patients and pregnant women
About the study
Demonstrate the relationship between dd-cfDNA levels and HLA antibodies in blood transplant recipient and Demonstrate the Molecular Microscope® (MMDx) Diagnostic System results in indication and protocol biopsies from lung transplants.
Sponsor: University of Alberta · Participants: 600 · Started: Nov 1, 2023
Contact the study team
- Konrad S Famulski, PhD DSc · Phone: 1 780 782 9463
- Robert Polakowski, PhD · Phone: 1 780 492 5091
Official record on ClinicalTrials.gov — NCT05837663
Locations in the U.S.
From ClinicalTrials.gov, data retrieved Oct 2, 2026. Each study sets its own eligibility; the study team decides who can join.